---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016285"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:13:15.954178+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q1 revenue down 50% to $0.7M; CFO Anish John to leave June 15

## Summary
- Revenue $0.7M, down 50% YoY; net operating income $2.9M vs loss of $9.4M.
- CFO Anish John departing June 15, 2023; no disagreements; search for replacement.
- Completed $13.86M equity raise in April from common stock sale.
- R&D expenses $2.8M (-45% YoY); G&A $3.7M (-35%); S&M $1.2M (-63%).
- Sold 70% of Razor Genomics; transitioning to capital-light kitted product model.

## SEC filing metadata
- accession: 0001493152-23-016285
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016285
- JSON: https://secwatch.observer/filing/0001493152-23-016285.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016285.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million, net income $2.9 million.
  - Period: the three months ended March 31, 2023
  - Revenue: $0.7 million
  - Net income: $2.9 million
  - Result: reported results
  source text: to create value for both patients and shareholders.” First Quarter 2023 Financial Results Consolidated revenues for the three months ended March 31, 2023, were approximately $0.7 million, a 50% decrease compared to the first quarter of 2022. Excluding DetermaRx revenue, the continuing operations revenue was $0.3 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm
- Executive change
  Anish John resigned as Chief Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 11, 2023, Oncocyte announced that Anish John, our Chief Financial Officer, will be leaving the Company on June 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.